Format

Send to

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2012 Jan 1;22(1):747-52. doi: 10.1016/j.bmcl.2011.03.006. Epub 2011 Mar 6.

Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.

Author information

1
Celgene Corporation, San Diego, 4550 Towne Centre Ct, San Diego, CA 92121, United States. gkpackardca@gmail.com

Abstract

The serine/threonine specific protein kinase B-Raf is part of the MAPK pathway and is an interesting oncology target. We have identified thieno[2,3-d]pyrimidines as a core scaffold of small molecule B-Raf inhibitors. The SAR of analogs in this series will be described.

PMID:
22137342
DOI:
10.1016/j.bmcl.2011.03.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center